|
|
|
0 members (),
298
guests, and
35
robots. |
|
Key:
Admin,
Global Mod,
Mod
|
|
S |
M |
T |
W |
T |
F |
S |
|
|
|
|
1
|
2
|
3
|
4
|
|
5
|
6
|
7
|
8
|
9
|
10
|
11
|
|
12
|
13
|
14
|
15
|
16
|
17
|
18
|
|
19
|
20
|
21
|
22
|
23
|
24
|
25
|
|
26
|
27
|
28
|
29
|
30
|
31
|
|
|
There are no members with birthdays on this day. |
#478829
Mon 22 Oct 2018 07:22:AM
|
Joined: Feb 2001
Posts: 381,903
Launch Director
|
OP
Launch Director
Joined: Feb 2001
Posts: 381,903 |
Roche's Tecentriq plus chemotherapy boosted lung cancer patients' survival by nearly five months, study data released on Monday showed, underscoring benefits of the Swiss group's immunotherapy but still leaving it trailing a rival's drug.  Source: Roche lands Tecentriq trial win, still trails Merck in lung cancer
David Cottle
UBB Owner & Administrator
|
|
CMS The Best Conveyancing solicitors conveyancing quotes throughout the UK
For any webhosting enquiries please email webmaster@aus-city.com
|
|
Forums60
Topics687,418
Posts722,029
Members2,957
| |
Most Online3,142
Jan 16th, 2023
|
|
|
|
|
Copyright 1996 - 2023 by David Cottle. Designed by David Bate Jr. All Rights Reserved.
By using this forum, the user agrees not to transfer any data or technical information received under the agreement, to any other entity without the express approval of the AUS-CITY Forum Admins and/or authors of individual posts (Forum Admins and DoD/USSPACECOM for the analysis of satellite tracking data).
Two-line elements (TLE) and all other satellite data presented and distributed via this forum and e-mail lists of AUS-CITY are distributed with permission from DoD/USSTRATCOM.
Reprise Hosting
|
|
